Clinical Read2026-06-02

Selinexor (XPORT-MF-034) - (SENTRY)

Name: Selinexor (XPORT-MF-034) - (SENTRY)
Start: 2026-06-02

Karyopharm Therapeutics Inc.KPTI

Indication: JAK inhibitor (JAKi) naïve myelofibrosis versus ruxolitinib alone
Stage: phase3
Event: Phase 3